BioSpace1d
Legal Challenge Over Lilly’s GLP-1 Shortages Highlights FDA’s Post-Chevron Vulnerability
Currently, Eli Lilly’s GLP-1 drugs Mounjaro and Zepbound (tirzepatide) are not on the FDA’s shortage list but compounded ...
FiercePharma2d
Pfizer led industrywide sales surge in Q3 after several quarters of dominance by Eli Lilly, Novo Nordisk
After six straight quarters in which Eli Lilly or Novo Nordisk achieved the highest year-over-year revenue growth among the ...
Wall Street Journal on MSN22h
Novo Nordisk Says White House Obesity Plan Is Step in Right Direction
The Biden administration on Tuesday proposed that weight-loss drugs be paid for by Medicaid and Medicare, potentially making ...
Eli Lilly and 2 More Drug Stocks to Buy After RFK-Inspired Drop
Eli Lilly, Novo Nordisk, and Amgen all look cheap. All of them could experience a massive boost to profits in the years to ...
Novo Nordisk Foundation CEO dismisses ‘Nokia risk’ as ‘fundamentally different’ for Denmark’s economy
Novo Nordisk Foundation CEO Mads Krogsgaard Thomsen said only 9 million people are using GLP-1s compared with 1 billion ...
Novo Nordisk: Supply Strains, Competition, And RFK Concerns Mask Solid Fundamentals
Novo Nordisk faces challenges in weight-loss sector, but acquisition and strong diabetes portfolio position it for future ...